Vaccine-maker Bharat Biotech said its next-generation typhoid vaccine Typbar-TCV has demonstrated safety and efficacy in a high-risk human challenge clinical study carried out at Oxford University.

Quoting findings from the study published in the journal The Lancet, the company claimed the vaccine produced 87% effectiveness.

The study is said to be the first to demonstrate that immunisation with Typbar-TCV was safe, well tolerated and would have significant impact on disease incidence in typhoid endemic areas that introduce the vaccine, a release from the company said.

Read more